Search Results

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Biocytogen Pharmaceuticals and ABL Bio Inc. today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).

Ablative Solutions, Inc., today announced that the TARGET BP I Pivotal Trial evaluating alcohol-mediated renal denervation with the Peregrine System ™ Kit met its primary endpoint, showing a statistically significant difference in 24-hour Ambulatory Blood Pressure between treatment and sham procedure at 3 months.

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”).

Despite these cuts, the FDA should be able to stay above a “trigger” level that would prevent it from collecting fees from the pharma industry and deprive it of approximately half of its annual funding, according to The Washington Post.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed Amy Ables, Ph.D . as chief strategy officer of the organization, effective immediately.

Ascentage Pharma (6855 HK) announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.

Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.